Canaud Bernard, Leray-Moragues H, Chenine Leila, Morena Marion, Miller George, Canaud Ludovic, Cristol Jean Paul
School of Medicine, Montpellier University, 34090 Montpellier, France.
MTX Consulting International, Rue des Carmelites, 34090 Montpellier, France.
J Clin Med. 2023 Jul 17;12(14):4732. doi: 10.3390/jcm12144732.
Tunneled central venous catheters (CVC) are mainly considered as a rescue vascular access option in dialysis but are still used on approximately one quarter of prevalent patients worldwide even though they are associated with poor performances and higher risks.
in this retrospective single-center study, we aimed to report on the clinical performances achieved with high-flow tunneled CVCs (DualCath or DCath) and compared them with arteriovenous accesses (AVAs, e.g., AV fistula, AV graft, and Thomas Shunt) in a hospital-based dialysis unit.
Sixty-eight stage 5 chronic kidney disease dialysis-dependent patients (CKD5D) receiving high volume hemodiafiltration were followed-up with for 30 months. The study consisted of two phases: baseline cross-sectional and longitudinal follow-ups of key performance indicators. Clinical performances consisting of effective blood flow and blood volume, recirculation, urea and ionic Kt/V, total Kt, ultrafiltration volume, and percent reduction in β2-M were measured monthly as part of quality control in our unit.
At baseline, the effective blood flow using a DCath was close to 400 mL/min, similar to an AVA. Recirculation with a DCath (7%, 6-13%) was higher than with an AVA. The diffusive dialysis dose delivered with a DCath (spKt and eKt/V) and convective dialysis dose achieved with a DCath were slightly lower than those achieved with AVAs, but they were still much higher than is recommended by guidelines. The percent reduction in β2-M achieved with a DCath was also 4 to 10% lower than that achieved with an AVA. On longitudinal follow-up, the main clinical performance indicators of DCaths (total Kt and total ultrafiltration volume, L/session) were maintained as very stable over time and close to those achieved with AVAs.
As shown in this study, high-flow DualCath tunneled two-single-lumen silicone catheters may be used to deliver high volume hemodiafiltration in a reliable and consistent manner without compromising clinical performance. These results relied on the specific design of the two silicone cannulas and the strict adherence to best catheter practices.
隧道式中心静脉导管(CVC)在透析中主要被视为一种挽救性血管通路选择,尽管其性能较差且风险较高,但在全球约四分之一的透析患者中仍在使用。
在这项回顾性单中心研究中,我们旨在报告高流量隧道式CVC(双腔导管或DCath)的临床性能,并将其与医院透析单元中的动静脉通路(AVA,如动静脉内瘘、动静脉移植物和托马斯分流术)进行比较。
对68例接受高通量血液透析滤过的5期慢性肾脏病依赖透析患者(CKD5D)进行了30个月的随访。该研究包括两个阶段:关键性能指标的基线横断面和纵向随访。作为我们单位质量控制的一部分,每月测量包括有效血流量和血容量、再循环、尿素和离子Kt/V、总Kt、超滤量以及β2 - M降低百分比等临床性能。
在基线时,使用DCath的有效血流量接近400 mL/分钟,与AVA相似。DCath的再循环率(7%,6 - 13%)高于AVA。DCath提供的弥散透析剂量(spKt和eKt/V)以及通过DCath实现的对流透析剂量略低于AVA,但仍远高于指南推荐值。DCath实现的β2 - M降低百分比也比AVA低4%至10%。在纵向随访中,DCath的主要临床性能指标(总Kt和总超滤量,升/次)随时间保持非常稳定,且接近AVA所达到的指标。
如本研究所示,高流量双腔隧道式双单腔硅胶导管可用于以可靠且一致的方式进行高通量血液透析滤过,而不会影响临床性能。这些结果依赖于两个硅胶套管的特殊设计以及对最佳导管操作的严格遵守。